Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   IRANIAN JOURNAL OF KIDNEY DISEASES (IJKD)   DECEMBER 2009 , Volume 3 , Number SUPPLEMENT 1 (12TH INTERNATIONAL CONGRESS OF NEPHROLOGY, DIALYSIS, AND TRANSPLANTATION); Page(s) 76 To 76.
 
Paper: 

ANTI-INFLAMMATORY EFFECTS OF SIMVASTATIN IN END STAGE RENAL DISEASE PATIENTS (POSTER PRESENTATIONS: P317)

 
 
Author(s):  SHAHBAZIAN H., ATRIAN A., EHSANPOUR A.
 
* 
 
Abstract: 

Introduction. End Stage Renal Disease (ESRD) is associated with higher levels of inflammatory biomarkers. This markedly higher inflammatory status can lead to faster rates of renal function loss, greater incidence of cardiovascular events, chronic malnutrition, erythropoietin resistance, and decrease in survival among dialysis patients. In addition to the cholesterol lowering effects of statins, they exert a number of so called “pliotropic”, vasculoprotective actions that include improvement of endothelial function, increased antioxidant properties, plaque stabilization, and immunomodulatory effects.
Methods. We conducted our prospective, randomized, controlled trial on 40 patients on chronic hemodialysis and divided them into two groups: simvastatin treatment group (20 mg daily, n = 25) and placebo group (n = 15). We measured hs-CRP, IL-6, Hb level, and WBC count at baseline and after 3 months. We also evaluated muscular and hepatic side effects of the drugs in these patients.
Results. Qualitative parameters were homogenous between the groups at baseline. Mean CRP levels was elevated at baseline in both groups (10.47 mg/L and 9.3 mg/L) with normal level of up to 3 mg/L. Mean hs-CRP levels decreased from 10.47 mg/L to 7.8 after 3 months in treatment group (P = 0.04) but in the control group, values were 9.3 mg/L at baseline and 10.3 mg/L after 3 months. Mean serum IL-6 level decreased from 5.13 pg/ml to 3.96 pg/ml in treatment group (P = 0.01) but in placebo group, increased from 4.0 pg/ml to 4.3 pg/ ml. After treatment, there was an elevation in mean Hb level in both groups from 10.1 g/dl to 10.9 g/dl in treatment group (P = 0.007) and 9.9 g/dl to 10.6 g/dl in control group (P = 0.06). WBC count was decreased from 8600 at mean baseline levels in treatment group to 6700 (P = 0.003) and from 7180 to 7150 in control group at the end of study. There were no significant changes in liver and muscle enzymes during and after therapy.
Conclusion. ESRD patients had elevated levels of inflammatory markers. Simvastatin significantly reduced serum hs-CRP, IL-6 levels, and WBC count in ESRD patients. Administration of simvastatin was safe in patients on hemodialysis.

 
Keyword(s): 
 
References: 
  • ندارد
 
  Yearly Visit 48
 
Latest on Blog
Enter SID Blog